349 related articles for article (PubMed ID: 20601092)
1. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.
Dong M; Yan BP; Liao JK; Lam YY; Yip GW; Yu CM
Drug Discov Today; 2010 Aug; 15(15-16):622-9. PubMed ID: 20601092
[TBL] [Abstract][Full Text] [Related]
2. Rho kinase (ROCK) inhibitors.
Liao JK; Seto M; Noma K
J Cardiovasc Pharmacol; 2007 Jul; 50(1):17-24. PubMed ID: 17666911
[TBL] [Abstract][Full Text] [Related]
3. Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?
Liao JK
Curr Atheroscler Rep; 2007 Nov; 9(5):384-8. PubMed ID: 18001621
[TBL] [Abstract][Full Text] [Related]
4. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine.
Shimokawa H; Satoh K
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233
[TBL] [Abstract][Full Text] [Related]
5. Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges.
Hu E; Lee D
Expert Opin Ther Targets; 2005 Aug; 9(4):715-36. PubMed ID: 16083339
[TBL] [Abstract][Full Text] [Related]
6. Vascular rho kinases and their potential therapeutic applications.
Budzyn K; Sobey CG
Curr Opin Drug Discov Devel; 2007 Sep; 10(5):590-6. PubMed ID: 17786858
[TBL] [Abstract][Full Text] [Related]
7. Rho-associated coiled-coil-forming kinases (ROCKs): potential targets for the treatment of atherosclerosis and vascular disease.
Zhou Q; Gensch C; Liao JK
Trends Pharmacol Sci; 2011 Mar; 32(3):167-73. PubMed ID: 21242007
[TBL] [Abstract][Full Text] [Related]
8. Rho kinase inhibitors as potential therapeutic agents for cardiovascular diseases.
Hu E; Lee D
Curr Opin Investig Drugs; 2003 Sep; 4(9):1065-75. PubMed ID: 14582450
[TBL] [Abstract][Full Text] [Related]
9. Rho kinase as a therapeutic target in cardiovascular disease.
Surma M; Wei L; Shi J
Future Cardiol; 2011 Sep; 7(5):657-71. PubMed ID: 21929346
[TBL] [Abstract][Full Text] [Related]
10. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications.
Zhou H; Li YJ
Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664
[TBL] [Abstract][Full Text] [Related]
11. Rho-kinase: important new therapeutic target in cardiovascular diseases.
Satoh K; Fukumoto Y; Shimokawa H
Am J Physiol Heart Circ Physiol; 2011 Aug; 301(2):H287-96. PubMed ID: 21622831
[TBL] [Abstract][Full Text] [Related]
12. The role of the RhoA/rho-kinase pathway in pulmonary hypertension.
Nossaman BD; Kadowitz PJ
Curr Drug Discov Technol; 2009 Mar; 6(1):59-71. PubMed ID: 19275543
[TBL] [Abstract][Full Text] [Related]
13. An Update on the Association of Protein Kinases with Cardiovascular Diseases.
Amin F; Ahmed A; Feroz A; Khaki PSS; Khan MS; Tabrez S; Zaidi SK; Abdulaal WH; Shamsi A; Khan W; Bano B
Curr Pharm Des; 2019; 25(2):174-183. PubMed ID: 30864507
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of clinical efficacy of fasudil for the treatment of pulmonary arterial hypertension.
Raja SG
Recent Pat Cardiovasc Drug Discov; 2012 Aug; 7(2):100-4. PubMed ID: 22670803
[TBL] [Abstract][Full Text] [Related]
15. Development of Rho-kinase inhibitors for cardiovascular medicine.
Shimokawa H; Rashid M
Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potentials of the Rho kinase inhibitor Fasudil in experimental autoimmune encephalomyelitis and the related mechanisms.
Yan Y; Yu J; Gao Y; Kumar G; Guo M; Zhao Y; Fang Q; Zhang H; Yu J; Jiang Y; Zhang HT; Ma CG
Metab Brain Dis; 2019 Apr; 34(2):377-384. PubMed ID: 30552558
[TBL] [Abstract][Full Text] [Related]
17. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening.
Yu B; Sladojevic N; Blair JE; Liao JK
Expert Opin Ther Targets; 2020 Jan; 24(1):47-62. PubMed ID: 31906742
[No Abstract] [Full Text] [Related]
18. Fasudil, a Rho‑kinase inhibitor, prevents intima‑media thickening in a partially ligated carotid artery mouse model: Effects of fasudil in flow‑induced vascular remodeling.
Zhang X; Zhang T; Gao F; Li Q; Shen C; Li Y; Li W; Zhang X
Mol Med Rep; 2015 Nov; 12(5):7317-25. PubMed ID: 26458725
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of favorable effects of Rho kinase inhibition on myocardial remodeling and systolic function after experimental myocardial infarction in the rat.
Mera C; Godoy I; Ramírez R; Moya J; Ocaranza MP; Jalil JE
Ther Adv Cardiovasc Dis; 2016 Feb; 10(1):4-20. PubMed ID: 26490279
[TBL] [Abstract][Full Text] [Related]
20. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats.
Kataoka C; Egashira K; Inoue S; Takemoto M; Ni W; Koyanagi M; Kitamoto S; Usui M; Kaibuchi K; Shimokawa H; Takeshita A
Hypertension; 2002 Feb; 39(2):245-50. PubMed ID: 11847192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
